Several decades of research support the involvement of transient receptor potential (TRP) channels in nociception. Despite the disappointments of early TRPV1 antagonist programs, the TRP family remains a promising therapeutic target in pain disorders. High-dose capsaicin patches are already in clinical use to relieve neuropathic pain. At present, localized injections of the side-directed TRPV1 agonist capsaicin and resiniferatoxin are undergoing clinical trials in patients with osteoarthritis and bone cancer pain. TRPA1, TRPM3, and TRPC5 channels are also of significant interest. This review discusses the role of TRP channels in human pain conditions.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ari-Pekka Koivisto is an employee of Orion Pharma. Thomas Voets has an interest in the TRPM3 antagonist program at Biohaven Pharmaceuticals. Michael J. Iadarola and Arpad Szallasi have no conflict of interest to declare.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)